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Background: Often concomitant patch test (PT) reactivity to palladium (Pd)
and nickel (Ni) is found.
Objectives: To determine whether lymphocyte transformation test (LTT)
could be useful in discrimination between cross‐reacting or distinct PT results,
and to compare the results with in vitro cytokine production upon Pd or Ni
stimulation.
Materials and Methods: The study population consisted of two groups:
13 individuals with Pd PT reactions (10 with concomitant Ni PT reaction,
3 individuals with only Pd PT reactivity) and 10 Ni/Pd PT negative individuals.
LTT and assessment of cytokine release (interferon‐gamma, interleukin‐5
[IL‐5], IL‐8, IL‐17A, tumor necrosis factor alpha) by cytometric bead assay
were performed.
Results: All 10 patients with positive PT to Ni and Pd showed positive LTT to
Ni (P< .05) as compared with the 10 Pd/Ni PT negative patients—but had no
significant LTT reaction to Pd. In all, 9 out of 10 Pd/Ni PT negative patients
were also LTT negative to Ni and 10 out of 10 to Pd. In the 3 only Pd PT
reactors 2 out of 3 remained LTT negative to Ni and 0 out of 3 to Pd. As a major
finding, cytokine production gave clearly enhanced IL‐5 response to Ni in Ni
PT positive individuals (P< .05), whereas Pd PT reactivity was not linked with
such enhanced IL‐5 production in vitro to Pd.
Conclusions: Pd and Ni sensitization are mostly found concomitantly, and
cross‐reactivity is questioned. By different LTT reactions and particularly IL‐5
production in vitro, predominant Ni sensitization becomes more evident.
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1 | INTRODUCTION
The main exposure of the general population to palla-
dium (Pd) is by jewelry and dental applications. About 8%
of the growing annual Pd production is used for dental
materials alone.1,2 As Pd alloys undergo corrosion, re-
leased metal ions may provoke contact allergic reactions
both in occupational and private setting.3 Correspond-
ingly, a recent data evaluation of the information net-
work of departments of dermatology (IVDK) reported Pd
(II) chloride as most frequent (ie, 3%) allergen of the
“dental metal series” detected in dental technicians with
occupational contact dermatitis.4 In the oral cavity, saliva
may facilitate corrosion of typically Pd containing dental
materials like dental crowns and bridges. Experience of a
Norwegian ambulatory for dental material intolerance
gives high allergy rates to nickel (Ni) (28%) and gold (Au)
(23%), but also to Pd (9%).5 Muris et al6 reported that
patients with Pd‐based dental materials more often pre-
sented with Pd reactivity in patch testing and lymphocyte
reactivity in vitro. Several authors found a strong re-
lationship between Ni and Pd allergy, and cross‐reactivity
of sensitized T cells was suspected.7‐10 Early experiments
by Pistoor et al9 show such cross‐reactivity of Ni‐reactive
T‐lymphocyte clones. Hindsen et al11 reported the in vivo
correlate of such cross‐reactivity by systemic Ni adminis-
tration. Both authors discuss that primary sensitization
was to Ni. In addition, Ni and Pd have another property in
common as they are described to induce T‐cell activation
also by direct binding to TLR4, according to Rachmawati
et al and Schmidt et al12,13 and Pd allergy has been a
subject of debate for decades and its prevalence is sup-
posed to be underestimated.14‐16 Moreover, Muris et al6
reported that by use of a different patch test (PT) pre-
paration, that is, Na2PdCl4, there was a substantial gain in
positive reactions. In fact, the “gold“ standard method to
confirm the clinical suspicion of metal allergy is the PT. In
particular for Ni allergy, the lymphocyte transformation
test (LTT) was described by various authors as a valid tool
to prove Ni sensitization in vitro.17‐23 In addition, some
authors have optimized Ni LTT conditions to improve
validity as compared with PT results.19,24
Analysis of cytokine production by Ni‐specific T cells
has suggested a mixed Th1 and Th2 cytokine production
in both T‐cell clones and peripheral blood mononuclear
cells (PBMCs).17,20,21,23 It was speculated that the type of
cytokine response to stimulation could modulate the re-
sulting immune response.25,26 Therefore, the allergen‐
induced cytokine production such as interferon‐gamma
(IFNγ), interleukin‐2 (IL‐2), IL‐12 (TH1‐related), IL‐4,
IL‐5, IL‐13 (TH2‐related), and TH17 associated IL‐17A as
well as tumor necrosis factor alpha (TNF‐α) and IL‐8 was
measured in supernatants of stimulated PBMC.20,27‐30
To our knowledge, results of LTT and PT with Ni and Pd
have rarely been directly compared. Thus, the aim of our
study was (a) to evaluate a potential link between Ni/Pd
reactivity in PT and LTT and (b) to determine whether in
vitro cytokine response to Ni and Pd might further distin-
guish cross‐reacting from isolated single Pd sensitization.
2 | MATERIALS AND METHODS
2.1 | Patients
Within the total number of patients patch tested every year
in the allergy unit of the Munich dermatology clinic, there
is always a series of patients being tested to standard and
dental metal series (series DKG17), including Pd(II)
chloride. Between March 2016 and March 2017, there were
70 of such patients (12 males [m], 58 females [f], mean age
61 ± 12.7 years) who underwent patch testing to dental
metal series. Based on positive or negative PT reaction to
Pd, 23 individuals (4 m, 19 f, mean age 63 ± 9.5 years)
within this consecutive patient series were recruited to
study the in vitro reactivity to Pd. All 23 patients gave their
written consent to blood donation for this investigation.
The study was approved by the local ethics committee. The
23 individuals consisted of 13 patients with Pd allergy
(10 out of 13 with additional Ni allergy, 3 out of 13 isolated
Pd allergy); 10 individuals without Pd or Ni allergy. All of
them had Pd containing dental materials such as crowns,
bridges, or inlays (as communicated to them by their
treating dentist), and one patient had Pd containing wed-
ding ring as an elicitor of local eczema.
From all 23 individuals, questionnaire‐based allergy
history was obtained. This included atopic diseases
(allergic rhinoconjunctivitis, allergic asthma, atopic
eczema); cutaneous metal intolerance reactions (such as
eczema caused by jewelry, wrist watches); oral compli-
cations in association with the dental bridges, crowns,
and dental alloys. The data are summarized in Table 1.
2.2 | Patch test
Patch testing was performed according to the guidelines
of the German Contact Dermatitis Research Group
(DKG) on the patient's upper back.31 Application time
was 2 days, and reading was done accordingly after 2, 3,
and 6 days. The cutaneous reactions were documented as
negative (no reaction), or positive by grading +, ++, and
+++. Doubtful and irritant reactions were also recorded
but considered as negative PT result. Test series were the
German standard series, a supplemental series, and at
least the dental metal series containing the Pd(II)
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chloride (1%) preparation. This means the official “pal-
ladium test reagent” given by the DKG was the Pd(II)
chloride preparation. Some patients were additionally
tested to the “dental technicians series” containing ac-
rylate and additive preparations. Most of the PT pre-
parations were from SmartPractice Europe (Reinbek,
Germany). According to the PT test results to Pd within
the 70 patients (see Table 2), the final 13 Pd PT positive
patients for the study had been subsequently recruited.
2.3 | Cell preparation and LTT
PBMCs were isolated from heparinized venous blood sam-
ples (40mL) by Ficoll‐Hypaque (Phadia, Freiburg, Germany)
density gradient centrifugation. The cells were resuspen
ded at 1× 106/mL in 10% human autologous serum‐
containing RPMI 1640 medium supplement with HEPES
(25mM), L‐glutamine, antibiotic‐antimycotic solution (Gibco
International, Karlsruhe, Germany), NEAA and MEM vita-
mins (Biochrom, Berlin, Germany). The LTT was performed
according to Summer et al.20,21 Cultures were prepared in
96‐well round‐bottom polystyrene culture plates (Nalge
Nunc International, Denmark) in parallel to assess pro-
liferative response (“radioactive assay”) and cytokine pro-
duction (“nonradioactive assay”). Cells were cultivated in
quadruplicate for 6 days. The following stimuli were used: As
controls T‐cell mitogen phytohaemagglutinine (PHA,
2.4 µg/mL; Biochrom) and tetanus toxoid as control recall
antigen (TT, 5 µg/mL; Chiron Behring, Berlin, Germany);
PdCl2 (Sigma‐Aldrich, Darmstadt, Germany)—to cover the
best stimulatory range—in the following nine concentra-
tions: 1.0mmol, 5.0 × 10−1mmol, 2.5 × 10−1mmol, 1.25×
10−1mmol, 6.25 × 10−1mmol, 3.13× 10−2mmol, 1.56×
10−2mmol, 7.81 × 10−3mmol, and 1.91× 10−4mmol. NiSO4
was used in the following previously already evaluated con-
centrations19: 2.5 × 10−2mmol, 1 × 10−2mmol, 7.5 × 10−3
mmol, and culture medium alone as additional control. On
day 5, cells were pulsed with 3H thymidine overnight, pro-
liferation was assessed on day 6 by incorporated radioactivity.
The proliferative response was expressed as a stimulation
index (SI), which was calculated by ratio of mean counts
per minute (cpm) of stimulated compared with un-
stimulated cultures.20 SI > 3 was regarded as positive. In the
parallel “nonradioactive” cultures, supernatants were col-
lected at day 6 after identical stimulation. The one excep-
tion was using instead of PHA, a mixture of phorbol‐
myristate‐acetate (PMA 15 ng/mL; Sigma‐Aldrich, Munich,
Germany) and ionomycin (1.5 µg/mL; Sigma‐Aldrich) as a
positive control. The nonradioactive cultures were also
performed in quadruplicate.
2.4 | Analysis of cytokine production
The supernatants of quadruplicate experiments were
pooled and tested for the following proinflammatory cyto-
kines: IFNγ (TH1 profile), IL‐5 (TH2), IL‐17A (TH17), and
IL‐8 (unspecific immune response). Cytokine production
was determined by use of fluorescent antibody marked
microparticles in a cytometric bead assay (BD Biosciences,
Heidelberg, Germany) and flow cytometry according to the
manufacturer's instructions (detection limit >0.5 pg/mL).
Cytokine levels upon stimulation were set in relation to
baseline cytokine production in unstimulated cultures
(medium only) as previously published.32
2.5 | Statistical analysis
Statistical analysis was done using IBM SPSS software
(IBM, Ehningen, Germany). The analysis was done using
TABLE 1 Characteristics of the 23 patients included for in
vitro experiments (13 patients with Pd PT reaction; 10 controls, Pd





Age 41‐75 y, mean 62.3 y 45‐76 y,
mean 64.8 y









Atopic diseasesc 6/13 2/10
Abbreviations: DMI, dental material intolerance; f, females; m, males; PT,
patch test; WRI, wedding ring intolerance (ie, eczema to Pd‐based
wedding ring).
aIn all, 10 out of 13 with additional Ni PT reaction.
bHistory of itching, erythema, eczema upon contact with jewelry, wrist
watch, and jeans button.
cAllergic rhinoconjunctivitis, allergic asthma and/or atopic eczema.
TABLE 2 Patch test reactivity of the 70 consecutive patients
tested to at least standard series and dental metals series
Pd(II) chloride
TotalNegative Positive
Nickel(II) sulfate Negative 52 3 55
Positive 4 11 15
Total 56 14 70
Note: In all, 14 had reacted to Pd(II) chloride, 15 to Ni(II) sulfate, and 11 out
of 14 Pd reactors also had Ni allergy.
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the Mann‐Whitney U test with a significance level
of P< .05.
3 | RESULTS
3.1 | PT reactivity
Within the initial consecutive 70 patients, 15 had PT
reactivity to Ni, 14 to Pd, and 11 out of 14 had con-
comitant Ni reactivity. The data with regard to Ni and Pd
reactivity are summarized in Table 2. Out of these 14 Pd
reactors, 13 consented to blood donation for in vitro ex-
periments. Their Pd reactivity was one patient +++,
five ++, and seven +. Three patients were mono-
sensitized to Pd, 10 had concomitant Ni reactivity. The
10 “controls” were patients without PT reactivity both to
Ni and Pd. Thus we divided the total of 23 patients into
three groups: group 1 = 10 patients with Pd and Ni PT
reactivity; group 2 = 3 patients with only Pd PT reactivity;
group 3 = 10 patients with no PT reactivity. The char-
acteristics of these 23 patients are shown in Table 3.
3.2 | Lymphocyte proliferative response
(LTT reactivity)
The LTT reactivity to Pd and to Ni was evaluated in re-
lation to the “gold standard” of respective positive PT.
Since frequently concomitant PT reactions to Pd and Ni
were found, we intended to detect potential different LTT
proliferative reaction patterns by using two approaches,
that is, (a) stimulation with PdCl2 and NiSO4 and (b)
comparing the three groups. When using PBMC of
patients and controls, the control stimuli showed a sig-
nificant mean proliferation response (SI) to PHA (group 1:
TABLE 3 Characteristics of the three patient groups who took part in the in vitro experiments





63, f Crown/bridges Pain, burning, redness + ++ AR
75, m Dental implant, crown/bridges Pain gingivitis + ++ None
72, f Dental implant Pain, redness, gingivitis ++ + AE
71, f Dental prosthesis Pain, burning, erythema, gingivitis,
gingiva swelling
+ ++ None
69, f Dental implant, crown/bridges Sensation of heat, pain, swelling + ++ AR
65, f Dental implant Itching, erythema ++ +++ None
57, f Crown/bridges Pain, erythema, gingivitis + ++ None
58, f Dental implant, crown/bridges Aphthae +++ + None
68, f Crown, bridges Gingivitis ++ +++ AE
57, f Dental implant, crown/bridges Pain, burning, redness, gingivitis ++ +++ None
Group 2
52, f Dental implant, crown/bridges Pain, gingivitis + − AE, AR, AA
63, f Dental implant, crown/bridges Pain, redness, gingivitis + − AR
41,f Wedding ring Eczema ++ − None
Group 3
64, f Dental implants Gingivitis − − None
68, m Dental implant, crown/bridges Pain, gingivitis − − None
67,f Dental prosthesis Burning − − None
58, m Crown/bridges Pain, burning − − AR
61, f Dental prosthesis Pain, gingivitis − − None
61, f Dental implants Gingivitis − − None
75, m Dental implant, crown/bridges Pain, gingivitis − − None
76, f Dental prosthesis Burning − − None
73, f Dental prosthesis Burning, erythema − − None
45, f Dental implant, crown/bridges Pain, burning erythema − − AR
Abbreviations: AA, allergic asthma; AE, atopic eczema, AR, allergic rhinitis; f, females; m, males.
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23.25 ± 6.9; group 2: 19.11 ± 4.67; group 3: 10.52 ± 2.87)
and the SI to TT reflected the varying immunization status
of the patients (group 1: 9.55 ± 1.68; group 2: 10.11 ± 7.01;
group 3: 17.65 ± 7.23.)
To optimize the LTT upon stimulation with Pd, 9 out
of 20 different concentrations are seen in preceding
control experiments as nontoxic and without “unspecific”
stimulatory effect were used in the actual experiments. In
the range of these nine different concentrations, we could
detect proliferation rates of the patients PBMC. In ac-
cordance with Pichler and Tilch,18 as a positive result, we
considered SI > 3 in at least one stimulation concentra-
tion. With regard to Ni, we could rely on three previously
evaluated, optimal stimulation concentrations. Accord-
ingly, all of the patients with a positive PT to Ni reacted
in the LTT to Ni with a SI > 3 in at least one Ni con-
centration (Figure 1A), that is, all were considered posi-
tive. The sensitivity and specificity of the LTT test to Ni
was up to 80% after stimulation with NiSO4 1 × 10
−5M.
The data are shown in Table 4. The 3 only Pd PT positive
patients and the 10 PT negative controls gave no sig-
nificant LTT reaction to Ni. On the other hand, at higher
Pd stimulation concentrations, the only Pd PT positive
patients (group 2) had also reacted to Pd stimulation with
a significant proliferation. Patients with concomitant Ni
reaction in PT had however, remained negative in Pd
stimulation (Figure 1B). The best results were obtained at
a concentration range from 5 × 10−4M to 1.25 × 10−4M
PdCl2. There was a perfect 100% sensitivity and specificity
of the LTT test after stimulation with PdCl2 2.5 × 10
−4M.
Interestingly patients with concomitant Ni PT reaction
showed proliferation in lower Pd concentrations (below
3.13 × 10−5M; Table 4).
3.3 | Cytokine expression
There was no significant production of IL‐8, IFNγ, and
IL‐17A after stimulation with Ni or Pd (data not
shown). PBMC of patients who were PT positive both to
Ni and Pd (group 1) produced IL‐5 in response to Ni
and Pd stimulation (Figure 2A). IL‐5 production after
Ni stimulation was more than 10‐fold increased in
comparison to Pd stimulation. The sensitivity and
specificity of the IL‐5 production after Ni stimulation
was up to 90% and 100%, respectively (Table 5). Patients
with concomitant Ni and Pd PT reactivity showed a
lower but still significant IL‐5 production after Pd sti-
mulation. Patients with single Pd contact allergy
(group 2) and controls (group 3) did not show an IL‐5
response when using Pd stimulation (Table 5). The best
discrimination level was reached by using a cut‐off level
of 10 pg/mL IL‐5.
4 | DISCUSSION
In dentistry, Pd is increasingly used due to its good solu-
bility with other metals, as well as its good mechanical
properties.33 Due to its oral “biocompatibility,” in Japan,
the government operates a specific mandate stating that all
government‐subsidized dental alloys have to include a Pd
content of at least 20%. Correspondingly this alloy is used
in approximately 90% of all Japanese dental treatments.34
Apart from the oral cavity, Pd exposure may also
occur following skin contact with consumer items.15 Pd is
released from dental alloys; even teeth brushing may
cause Pd release.35
Pd allergy is a potential elicitor of oral lesions associated
with dental alloys. PT remains the gold standard for diag-
nosing oral disease resulting from an allergy to metallic
dental materials. However, isolated Pd sensitization is rarely
found, and concomitant PT reactivity to both Ni and Pd is
reported.10 The review of Faurschou et al15 confirms that Pd
allergy is common and nearly always observed together
with Ni allergy. Analysis of the PT data as registered by the
DKG in 2006‐2016 has shown that out of 1017 Pd PT po-
sitive individuals 782 (76.9%) had also reacted to Ni, that is,
about 235 were monosensitized to Pd (Prof. Geier, personal
communication, University of Göttingen).
Upon using a potentially more appropriate PT pre-
paration, that is, sodium tetrachloropalladate36 in 23 Pd PT
positive patients, cross‐reactivity with some of the nickel
salts tested was found in 17 out of 23. Subsequently, Muris
et al6 reported in 2014 that “significantly more Pd mono-
sensitized patients were found in the oral disease group in
the metal allergic contact dermatitis group.” The authors
speculate, that cutaneous Ni exposure may preferentially
induce Ni‐specific T cells that cross‐react with Pd as op-
posed to more often Pd‐specific reactivity by oral Pd ex-
posure. This is also supported by two observations: (a) Ni
allergy is more frequent in females, and our patients are
almost only females. (b) Exposure to Pd from dental re-
storations is expected to be similar in men and women.15
With regard to Ni allergy, the LTT has been optimized for
the evaluation of Ni reactivity in vitro.19,23,24 In addition,
simultaneous assessment of released cytokines was
suggested to better discriminate allergic from unspecific
reactivity. Examples are IFNγ production or, more re-
cently also, an assessment of TH2‐related cytokines.
Jakobson et al37 found that PBMC from nickel‐allergic
individuals responded to Ni with significantly increased
production of IL‐4, IL‐5, IL‐13, and IFN‐γ, but not IL‐
12, as compared with healthy controls. Minang et al28
demonstrated that IL‐10 is of importance for regulating
the Ni‐mediated immune response to Ni. TH1 type
(IFN‐γ) responses were supposed to be downregulated
by IL‐10.38 Bordignon et al39 investigated blood samples
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from 40 patients who were patch tested. By enzyme‐
linked immunospot (ELISpot) assay, they assessed
IFN‐y and IL‐10 production in vitro and found that (a)
PBMC of Ni and Pd PT negative patients only produced
IL‐10 both to Ni and Pd stimulation, (b) PBMC of only
Ni PT positive patients produced IFN‐y to Ni but only
IL‐10 to Pd stimulation, (c) PBMC of Ni and Pd PT
double‐positive patients produced IFN‐y to Ni but again
only IL‐10 to Pd stimulation, (d) PBMC of only Pd PT
positive patients produced IL‐10 to Ni and IFN‐y to Pd.
FIGURE 1 A, Proliferation of PBMC of patients with double‐positive PT to Ni and Pd (group 1), positive PT only to Pd (group 2),
and negative PT to Ni and Pd (group 3) after 6 days of stimulation with Ni in three different concentrations. SI is given; a SI > 3
is regarded as positive reaction (red line); positive control PHA gave no differences in the three groups; *P< .05. B, Proliferation
of PBMC of patients with double‐positive PT to Ni and Pd (group 1), positive PT only to Pd (group 2), and negative PT to Ni and
Pd (group 3) after 6 days of stimulation with PdCl2 in nine different concentrations. SI is given; a SI > 3 is regarded as positive
reaction (red line); positive control PHA gave no differences between the three groups; *P< .05. PBMC, peripheral blood
mononuclear cells; PHA, phytohaemagglutinine; PT, patch test; SI, stimulation index
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They concluded that Pd is often “cross‐reacting” with
dominant Ni sensitization and only isolated Pd PT
positivity and distinctive cytokine pattern in vitro might
indicate relevant Pd allergy. Unfortunately, in these
experiments no proliferation assays were included.
In 2012 Muris et al40 again reported on Pd‐induced
TH2 cytokine responses in vitro. Most of the patients
in this study were however, double‐positive to Ni and
Pd in PT.
Spiewak et al30 and Czarnobilska et al41 reported that
Ni PT reactivity was reflected by IL‐5 production in vitro.
Recently Summer et al42 could show that the determina-
tion of the IL‐5/IL‐8 response ratio in vitro could optimize
detection of patients with Ni contact allergy. Thus, the aim
of the present study was to compare PT and LTT reactivity
with both Ni and Pd and to assess potential discrimination
benefit from cytokine assessment. With the restriction of
the rather low number of individuals tested, the use of Pd
(II) chloride as reagent and the here not assessed IL‐13, we
can draw the following conclusions:
As compared with Ni and Pd PT negative patients we
could show that the 10 Pd and Ni double PT positive
patients had clear‐cut LTT reactivity to Ni (10 out of 10)
and none to Pd.
Based on Ni and Pd PT double‐negative patients we
could demonstrate, that PBMC of these patients had
neither LTT reactivity nor IL‐5 production both to Ni
or to Pd stimulation. Furthermore, the PBMC of Pd PT
positive Ni negative patients did not respond with IL‐5
production to Ni stimulation in vitro. As Pd stimula-
tion in vitro had induced IL‐5 production in vitro to a
much lower extent than Ni in the 10 Pd and Ni PT
reactive patients, it seems that Ni sensitization is
predominant and “isolated” relevant Pd PT reactivity
—as opposed to Ni reactivity—is not characterized by
IL‐5 response. Accordingly, Kobayashi et al43 reported
from a mouse model on Pd‐sensitized animals, that
after rechallenge (a) some of the isolated Pd‐specific
clones produced Th1‐cytokines (like IFNy and TNF‐α),
(b) IL‐10 production was also seen, but (c) TH2 cyto-
kines (ie, IL‐4 and IL‐5) were not increased.
Taken together, marked IL‐5 response upon in vitro sti-
mulation of PBMC by Ni is found in Ni allergic individuals.
The LTT with additional analysis of the IL‐5 response can be
a tool to distinguish between Pd and Ni cross‐reactivity and
can help to identify patients with a Pd contact allergy, which
means a proliferative response and at the same time lacking
IL‐5 response after stimulation with Pd. This is different from
Muris et al6 who also described 2 years after the above‐
mentioned publication 13 Pd PT positive patients within the
16 IL‐5 reactors observed in a group of 71 patients. In a
subsequent publication, Muris et al44 again reported on such
IL‐5 reactivity, however, most of the patients were again PT
double‐positive to Ni and Pd. Furthermore our here used
LTT protocol is not comparable to the assays in their studies,
which for example, also includes cytokine supplemented
culture medium for the “cytokine experiments.”
In summary, the present study confirms, that Ni and
Pd reactivity are often found simultaneously in PT, and
that primary Ni sensitization is characterized by distinct
LTT reactivity together with additional IL‐5 response in
vitro. The combination of LTT test and IL‐5 measurement
TABLE 4 Sensitivity and specificity of the LTT test to Ni and Pd calculated for the cut‐off level of the stimulation index, SI > 3
LTT Ni and Pd PT positive vs PT negative Single Pd PT positive vs PT negative
Metal Concentration Sensitivity, % Specificity, % P value Sensitivity, % Specificity, % P value
NiSO4 2.5 × 10
−5M 100 60.00 .0108* 33.33 66.66 .999
NiSO4 1 × 10
−5M 80.00 80.00 .0230* 0.00 80.00 .999
NiSO4 7.5 × 10
−6M 60.00 100 .0108* 0.00 100 .999
PdCl2 1 × 10
−3 33.33 100 .4737 33.33 100 .2308
PdCl2 5.0 × 10
−4 10.00 100 .9999 66.67 100 .0385*
PdCl2 2.5 × 10
−4 20.00 100 .4737 100 100 .0035**
PdCl2 1.25 × 10
−4 40.00 100 .0867 33.33 100 .2308
PdCl2 6.25 × 10
−4 40.00 100 .0867 33.33 100 .2308
PdCl2 3.13 × 10
−5 50.00 100 .0325* 33.33 100 .2308
PdCl2 1.56 × 10
−5 50.00 100 .0325* 00.00 100 .999
PdCl2 7.81 × 10
−6 40.00 100 .0867 33.33 100 .2308
PdCl2 3.91 × 10
−6 60.00 100 .0108** 33.33 100 .2308
Abbreviations: LTT, lymphocyte transformation test; PT, patch test.
*p< .05, **p< .01
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FIGURE 2 A, IL‐5 production of PBMC of patients with double‐positive PT to Ni and Pd (group 1), positive PT only to Pd (group
2) and negative PT to Ni and Pd (group 3) after 6 days of stimulation with NiSO4 in three different concentrations. IL‐5 concentration
is given in pg/mL; positive control with PMA/ionomycion gave no differences between the three groups; *P< .05. B, IL‐5 production
of PBMC of patients with positive PT both to Ni and Pd (group 1), positive PT only to Pd (group 2), and negative PT to Ni and Pd
(group 3) after 6 days of stimulation with PdCl2 in nine different concentrations. IL‐5 concentration is given in pg/mL; positive
control with PMA/ionomycion gave no differences between the three groups; *P< .05 and **P< .01. IL‐5, interleukin‐5;
PBMC, peripheral blood mononuclear cells; PMA, phorbol‐myristate‐acetate; PT, patch test
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can be a helpful tool to distinguish between a “real”
contact allergy to Pd or cross‐reactivity with Ni.
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